Premium
Autologous bone marrow transplantation for acute myeloid leukaemia in remission: a preliminary report
Author(s) -
Bradstock K. F.,
Posen J.,
Kabral A.,
Hughes W. G.,
Koutts J.,
Robertson T. I.,
Lee C. H.,
Castaldi P. A.
Publication year - 1990
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1990.tb00364.x
Subject(s) - medicine , surgery , cyclophosphamide , bone marrow , chemotherapy , transplantation , sepsis , complete remission , leukemia
Abstract Autologous bone marrow transplantation, using unpurged cryopreserved autologous marrow, was performed on ten adult patients with acute myeloid leukaemia in remission. Seven patients were in first chemotherapy‐induced remission of their disease, while three were in later remission. Patients ages ranged from 24 to 52 years, with a median of 38.5 years. Conditioning therapy consisted of oral busulphan 16 mg/kg over four days and intravenous cyclophosphamide 60 mg/kg on two days. Bone marrow cells were thawed and infused two days later. All patients showed signs of marrow engraftment, however this was delayed in comparison with patients receiving allogeneic transplants. All patients developed fever requiring antibiotic therapy and one patient died of overwhelming sepsis. Another patient died of hepatic veno‐occlusive disease two months after transplant. Serious, but non‐fatal, hepatic complications occurred in two other patients. One patient, transplanted in third remission, relapsed 16 months post‐autograft. No other relapses have been seen, with one second remission patient remaining leukaemia‐free at 24 months, and six first remission patients in continuing remission 11 to 23 (median 20) months post transplant. These encouraging results require confirmation in a randomised clinical trial comparing autologous marrow transplantation versus standard chemotherapy.